LL-37: Immune Modulation, Viral Defense, and Senescent Cell Clearance

by Dr. James Ross

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

LL-37 Activates Multiple Immune Pathways

LL-37 is a cationic peptide with an alpha-helical structure that can bind to microbial and viral membranes, disrupt them, and eliminate invading organisms. Beyond antimicrobial action, LL-37 plays a significant immunomodulatory role. It binds strongly to nucleic acids, enhances toll-like receptor (TLR) activation, and transports nucleic acid complexes into cells. Once inside, LL-37 triggers inflammatory and interferon responses through both endosomal receptors and cytosolic sensors such as cGAS-STING and RIG-I–like receptors (RLRs). These pathways allow the immune system to recognize pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), driving interferon production and protective immune responses.

SARS-CoV Blocks Interferon via STING Disruption

SARS coronavirus uses its papain-like protease (PLpro) to block host defenses by interfering with the STING-TRAF3-TBK1 signaling complex. Normally, this pathway activates type I interferons through IRF3 phosphorylation. PLpro disrupts the interaction of these key proteins, reduces their ubiquitination, and prevents interferon induction, thereby weakening innate immunity. Interestingly, LL-37–DNA complexes are capable of stimulating interferon responses in different immune cells, providing a potential counterbalance to viral immune evasion.

LL-37 Inhibits Cathepsin L and Limits Viral Entry

LL-37 directly inhibits cathepsin L, a protease required for SARS-CoV activation during cell entry, at nanomolar concentrations. While suppressing cathepsin L, it can enhance activity of cathepsins S and K. By selectively blocking cathepsin L, LL-37 may hinder coronavirus priming and replication.

cGAS Activation: Balancing Damage Sensing and Regeneration

cGAS detects DNA from damaged mitochondria or stressed cells and activates inflammation through interferon pathways. In sepsis, excessive cGAS activity can worsen outcomes by promoting inflammation and delaying tissue repair. However, studies show that low-level cGAS activation promotes the clearance of damaged or mitotically arrested cells without triggering excessive cytokine storms. This controlled activation allows apoptosis of abnormal cells while avoiding widespread inflammation.

LL-37 Protects Against Sepsis and Pyroptosis

Animal studies demonstrate that LL-37 protects white blood cells from pyroptosis triggered by PAMPs and DAMPs such as LPS and ATP. LL-37 suppressed IL-1β expression, caspase-1 activation, inflammasome formation, and cell death, preventing excessive immune destruction. This ability to block pyroptosis highlights its therapeutic potential in sepsis and systemic inflammation.

Dose-Dependent Effects: Protection vs. Inflammation

At low concentrations, LL-37 prevents apoptosis of neutrophils and protects immune function. At high concentrations, however, LL-37 can cause necrosis, worsen inflammation, and contribute to atherosclerosis. Elevated LL-37 in atherosclerotic plaques has been linked to recruitment of inflammatory cells and plaque growth. Thus, its beneficial or harmful role depends on dosage and physiological context.

cGAS, DNA Stress, and Controlled Cell Death

Research shows that chromatin-bound cGAS interferes with DNA repair under genomic stress, accelerating micronucleus formation and cell death. During mitotic errors, slow cGAS-dependent IRF3 phosphorylation accumulates, triggering apoptosis without inflammation. This mechanism selectively eliminates cells with division errors, preventing them from propagating damage.

Angiogenesis Regulation and Aspirin’s Modulating Effect

LL-37 induces angiogenesis in endothelial cells through PGE2-EP3 signaling. However, aspirin can block this pro-angiogenic effect. In situations where angiogenesis may be detrimental—such as viral infection or excessive inflammation—aspirin could help redirect LL-37’s activity toward cell clearance rather than vessel growth.

LL-37 Promotes Phagocytosis and Senescent Cell Clearance

LL-37 enhances macrophage phagocytosis of bacteria by upregulating Fc receptors and TLR4. This effect contributes to bacterial defense and may also support clearance of senescent cells, particularly after resistance exercise, when senescent progenitor cells in skeletal muscle decrease. Activation of phagocytosis by LL-37 links innate immunity with rejuvenation of tissues.

cGAS in Senescence and Aging

cGAS is essential for detecting senescent cells. It contributes to the senescence-associated secretory phenotype (SASP), which flags damaged cells for immune clearance. While excessive activation can cause collateral damage to healthy tissue, moderate cGAS activity ensures that “zombie” cells are eliminated, reducing risks of cancer, fibrosis, and chronic inflammation.